Diagnostics

Objective medication adherence calculator – a tool to aid patient adherence and optimise drug dosage

Assessing adherence to medication is an essential element in the ongoing treatment of patients with chronic disease as well as in the development and trialling of new drugs. RCSI has developed a novel data-driven decision support tool for clinicians to improve patient adherence and personalise medication dosage in chronic conditions such as COPD and asthma.

This technology is being commercialised by RCSI spin-out company Phyxiom.

Novel epigenetic biomarkers and targets for metastatic colorectal cancer

Using an extensive proprietary epigenetic dataset. researchers at RCSI have developed a novel, patentedbiomarker panel to identify patients with colorectal cancer who are at high risk of developing metastatic disease (mCRC) and a series of novel validated therapeutic targets. The team are seeking industry partners to co-develop thisstrategy of biomarker-led early intervention with directed therapies to help to improve outcomes for this high-risk group.